PREDICT-IVI: Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels

Sponsor
Goethe University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04263571
Collaborator
Pharmacosmos A/S (Industry), University Hospital Muenster (Other)
100
2
56.6
50
0.9

Study Details

Study Description

Brief Summary

The study is a multidisciplinary study, which involves all kind of medical specialties. Patients, who are scheduled for elective surgery, will be seen at a multidisciplinary anaesthesia/Patient Blood Management (PBM) clinic and screened for anaemia prior to surgery. Anaemic patients will eventually be treated with 500mg of iron isomaltoside.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hgb levels, standard iron parameters and hepcidin will be assessed. Additional parameters that might influence Hgb or IVI levels will be documented.

    All main analyses will be pre-defined in detail in a statistical analysis plan. In order to analyse the responsiveness to IVI, the change in Hgb levels from PBM clinic to day 0 will be analysed using multivariable regression models. The association of change in Hgb and hepcidin will be analysed adjusting for potentially confounding factors as age, gender or number of days from PBM clinic to surgery. The correlation of hepcidin and standard iron parameters will be assessed. Based on the increase in Hgb levels, responders to IVI will be defined. The definition of good- bad responder in terms of delta Hgb levels depends on the time between IVI substitution and surgery. ROC analyses will be performed and potential predictors (e.g. hepcidin, ferritin) will be compared concerning the area under the ROC curve (AUC).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels Prior to Elective Surgery
    Actual Study Start Date :
    Apr 12, 2019
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Hemoglobin level [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic.]

      Change in hemoglobin level after IV iron treatment

    Secondary Outcome Measures

    1. Hepcidin [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic.]

      Serum hepcidin level prior to IV iron Infusion (ng/ml)

    2. Serum iron [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Serum iron prior to IV iron

    3. Transferrin saturation [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Transferrin saturation prior to IV iron

    4. Ferritin levels [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Ferritin levels prior to IV iron

    5. Transferrin protein [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Transferrin protein prior to IV iron

    6. Soluble transferrin receptor [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Soluble transferrin receptor prior to IV iron

    7. Number of reticulocyte counts [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Number of reticulocyte counts

    8. Mean corpuscular hemoglobin (MCH) [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Mean corpuscular hemoglobin prior to IV iron

    9. Level of reticulocyte-Hb in g/dl [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Level of reticulocyte-Hb prior to IV iron

    10. Level of Phosphate in serum [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Level of Phosphate in serum prior to IV iron

    11. Corpuscular hemoglobin of reticulocytes (CHr) [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Value of each parameter prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Corpuscular hemoglobin of reticulocytes (CHr) prior to IV iron

    12. Leucocyte count [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. value prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Leucocyte count prior to IV iron Infusion

    13. Level of C-reactive Protein [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. value prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Level of C-reactive Protein prior to IV iron Infusion

    14. Level of Serum Procalcitonin [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. value prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Level of Serum Procalcitonin prior to IV iron Infusion

    15. Length of stay in the hospital [Up to 12 weeks]

      Length of stay in the hospital

    16. blood transfusions [Up to 12 weeks]

      Number of blood transfusions

    17. Diagnosis Related Groups (DRGs) related to infections [Up to 12 weeks]

      Diagnoses encoding infections

    18. Correlation of hepcidin and IV iron parameters [4-28 days prior to elective surgery, IV iron is infused in the anesthesia pre-assessment clinic. Correlation of values prior to IV iron infusion, prior to surgery, at day 1, 3 and 7 or day of release from hospital]

      Correlation of serum hepcidin and change of Hgb from baseline to day of surgery, day 1, 3 and 7 after surgery and the day of discharge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • informed consent

    • iron deficiency anemia

    • elective surgery planned during the next 4 to 28 days

    Exclusion Criteria:
    • Contraindications for an IV iron Infusion severe infections, hepatocellular carcinoma, liver metastases, acute severe asthma, a simultaneous oral iron medication, another IV iron preparation, iron overload, chronic renal failure and regular IV iron substitution

    • Pregnancy or lactation

    • Allergy against iron

    • chronic renal failure on dialysis

    • iron overload

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Frankfurt Frankfurt Hessen Germany 60590
    2 Dept. of Anesthesiology, Intensive Care and Pain Medicine, UKM Muenster Germany 48149

    Sponsors and Collaborators

    • Goethe University
    • Pharmacosmos A/S
    • University Hospital Muenster

    Investigators

    • Principal Investigator: Andrea U Steinbicker, Prof Dr MPH, Johann Wolfgang Goethe-University, Dept. of Anesthesiology, Intensive Care and Pain Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Priv.-Doz. Dr. Andrea Ulrike Steinbicker, Prof. Dr. Andrea Ulrike Steinbicker, Goethe University
    ClinicalTrials.gov Identifier:
    NCT04263571
    Other Study ID Numbers:
    • 06-AnIt-18
    First Posted:
    Feb 11, 2020
    Last Update Posted:
    Oct 8, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Priv.-Doz. Dr. Andrea Ulrike Steinbicker, Prof. Dr. Andrea Ulrike Steinbicker, Goethe University

    Study Results

    No Results Posted as of Oct 8, 2021